Category Archives: AZBio News

Health Innovation Leaders Respond to the Executive Order on Most Favored Nations Pricing

Posted on by

On May 12, 2025, President Donald J. Trump signed Executive Order  DELIVERING MOST-FAVORED-NATION PRESCRIPTION DRUG
PRICING TO AMERICAN PATIENTS that establishes a requirement for Most Favored Nations Prescription Drug Pricing.

Section 5 of the EO states:  “Within 30 days of the date of this order, the Secretary shall, in coordination with the Assistant to the President for Domestic Policy, the Administrator for the Centers for Medicare and Medicaid Services, and other relevant executive department and agency (agency) officials, communicate most-favored-nation price targets to pharmaceutical manufacturers to bring prices for American patients in line with comparably developed nations.” 

The intent is to obtain the lowest prices offered by drug companies in other wealthy countries, known as “most-favored-nation” (MFN) pricing, and to take action if those prices aren’t extended to Americans. It also calls for direct-to-consumer programs, drug importation from countries with lower costs, and antitrust enforcement against companies that block price competition.Continue reading→

Responses to The Administration’s Section 232 Inquiry into Pharmaceutical Imports

Posted on by

“The Trump administration’s Section 232 inquiry into pharmaceutical imports represents a pivotal moment for the sector. Leaders in pharmaceutical supply chains must adjust and create solutions to maintain access to essential medications while responding to the changing trade environment.” — Srihari Rangarajan, EY Americas Life Sciences Supply Chain LeaderContinue reading→

PREVAIL Act Reintroduced The PREVAIL Act to Address

Posted on by

The Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act  supports American inventors, encourages investments in intellectual property, secures U.S. global technology leadership, and safeguards both economic and national security.

“The PREVAIL Act will empower startups and small businesses by realigning the Patent Trial and Appeals Board with Congress’s original intent,” — Dr. Hans Sauer, Deputy General Counsel and Vice President for Intellectual Property, Biotechnology Innovation Organization (BIO).

Continue reading→

AdvaMed CEO Calls for “Zero for Zero” Reciprocal Tariffs on Medtech with U.S. Trading Partners 

Posted on by

WASHINGTON, – Scott Whitaker, president and CEO of AdvaMed, the Medtech Association, today called for a reciprocal “zero for zero” model with respect to tariffs among U.S. trading partners for medical technologies. In an interview with Joe Mullings of the Mullings Group, Whitaker stated that tariff-free trade is critical to maintaining the highly competitive nature of the medtech industry, which keeps prices down and serves patients nationwide and globally with a robust breadth and depth of lifesaving medtech. Continue reading→